GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adults aged 60 or over.

GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human medicines committee.

making it the first shot greenlit for use in this age group to guard against RSV. Global vaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and older ...

The Pfizer vaccine is already approved in the EU for those aged 16 and older The EU's medicines agency (EMA) has approved the Pfizer-BioNTech vaccine for 12-15 year olds - the first jab allowed ...

It could be available to people over 60 within months, officials say. "Today's approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life ...

and against which vaccines currently approved at EU wide-level show little protection," the Amsterdam-based agency said. The BTV-3 strain of the virus was first detected in the Netherlands in ...

There isn't a vaccine for kids yet but high-risk infants often get monthly doses of a protective drug during RSV season,and European regulators recently approved the first one-dose option.